Korean J Hematol.
2004 Jun;39(2):59-65.
The Clinical Efficacy of R-CHOP Chemotherapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma
- Affiliations
-
- 1Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea. drjejung@chonnam.ac.kr
- 2Genome Research Center for Hematopoietic Diseases, Chonnam National Hwasun Hospital, Hwasun, Jeonnam, Korea.
- 3Department of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Korea.
- 4Department of Hematology/Oncology, Gyeongsang National University Hospital, Jinju, Korea.
- 5Department of Hematology-Oncology, Keimyung University School of Medicine, Daegu, Korea.
- 6Department of Hematology/Oncology, Ajou University School of Medicine, Suwon, Korea.
Abstract
- BACKGROUND
In combination with standard-dose CHOP (cyclophosphamide, vincristine, adriamycin, and prednisolone), the addition of rituximab produces a better clinical response in the treatment of aggressive B-cell non-Hodgkin's lymphoma (NHL) than CHOP alone.
METHODS
Thirty-four patients with previously untreated diffuse large B-cell NHL received at least three or four cycles of rituximab 375 mg/m2 or 500 mg per dose on day 1 of each cycle in combination with CHOP chemotherapy.
RESULTS
The median age of patients were 61.5 years (range, 28-83 years). After the end of therapy, twenty-five patients (73.5%) experienced a complete response, four patients (11.8 %) had a partial response, and two patients (5.9%) were classified as having progressive disease. The median follow-up duration was 9.4 months (range, 0.2-19.5 months) and 1-year overall survival and progression free survival was 84.8+/-8.7% and 80.3+/-9.4%, respectively. Two patients (5.9%) experienced fever, myalgia, and skin eruption due to rituximab. Neutropenia of grade 3 or 4 occurred in thirty-one patients (91.2%).
CONCLUSION
The benefits of rituximab in combination with CHOP chemotherapy include high response rates and good tolerance. However, further prospective, randomized studies are needed to draw definitive conclusions.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
- Diffuse Large B-cell Lymphoma Successfully Treated in a Pregnant Patient
- Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
- Two Cases of Primary Esophageal Diffuse Large B Cell Lymphoma: Therapeutic Considerations and a Literature Review
- Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
